About   Help   FAQ
Phenotypes Associated with This Genotype
Genotype
MGI:4867688
Allelic
Composition
Gba1tm1.1Pmis/Gba1tm1.1Pmis
Tg(Mx1-cre)1Cgn/0
Genetic
Background
involves: C57BL/6 * CBA
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gba1tm1.1Pmis mutation (0 available); any Gba1 mutation (43 available)
Tg(Mx1-cre)1Cgn mutation (7 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
• thymi in pIpC-treated mice exhibit a greater than 10-fold increase in MHCII+ (IA/IE) and B220+ (CD45R) cells compared with wild-type mice
• up to 8-fold in pIpC-treated mice
• in pIpC-treated mice
• pIpC-treated mice exhibit increased cells positive for CD69 and CD44 compared with wild-type mice
• T cell maturation in pIpC-treated mice is impaired compared to in wild-type mice
• pIpC-treated mice exhibit increased serum levels of IL1b, IL1a, IL2, IL3, IL6, IL9, IL10, IL13, Ccl2, Ccl3, Ccl4, TNF-alpha, GM-CSF (granulocyte-macrophage colony-stimulating factor), and IFN-gamma compared with wild-type mice
• pIpC-treated mice exhibit decreased MIP-1alpha (Ccl3), MCP-1 (Ccl2), and MIP-1beta (Ccl4) serum levels compared with wild-type mice

skeleton
• osteoblast differentiation of stromal cells from pIpC-treated mice is reduced compared to for wild-type cells
• in vivo osteoblast differentiation in pIpC-treated mice is reduced compared to in wild-type mice
• pIpC-treated mice exhibit Gibbus formation unlike wild-type mice
• in pIpC-treated mice
• pIpC-treated mice exhibit reduced trabecular bone volume with increased trabecular space compared with wild-type mice
• pIpC-treated mice exhibit avascular osteonecrosis unlike wild-type mice
• at 14 months of age, pIpC-treated mice exhibit reduced bone formation compared with wild-type mice
• however, bone formation rate is normal at 3 months of age in pIpC-treated mice

liver/biliary system
• in pIpC-treated mice
• in pIpC-treated mice

growth/size/body
• in pIpC-treated mice
• in pIpC-treated mice
• in pIpC-treated mice
• up to 8-fold in pIpC-treated mice
• in pIpC-treated mice

homeostasis/metabolism
• pIpC-treated mice exhibit increased serum levels of IL1b, IL1a, IL2, IL3, IL6, IL9, IL10, IL13, Ccl2, Ccl3, Ccl4, TNF-alpha, GM-CSF (granulocyte-macrophage colony-stimulating factor), and IFN-gamma compared with wild-type mice
• pIpC-treated mice exhibit decreased MIP-1alpha (Ccl3), MCP-1 (Ccl2), and MIP-1beta (Ccl4) serum levels compared with wild-type mice

hematopoietic system
• thymi in pIpC-treated mice exhibit a greater than 10-fold increase in MHCII+ (IA/IE) and B220+ (CD45R) cells compared with wild-type mice
• up to 8-fold in pIpC-treated mice
• in pIpC-treated mice
• pIpC-treated mice exhibit increased cells positive for CD69 and CD44 compared with wild-type mice
• T cell maturation in pIpC-treated mice is impaired compared to in wild-type mice
• in the spleen and liver of pIpC-treated mice
• in pIpC-treated mice

integument
• in the extremities of pIpC-treated mice

cellular
• osteoblast differentiation of stromal cells from pIpC-treated mice is reduced compared to for wild-type cells
• in vivo osteoblast differentiation in pIpC-treated mice is reduced compared to in wild-type mice

endocrine/exocrine glands
• thymi in pIpC-treated mice exhibit a greater than 10-fold increase in MHCII+ (IA/IE) and B220+ (CD45R) cells compared with wild-type mice

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
Gaucher's disease type I DOID:0110957 OMIM:230800
J:167081


Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
03/12/2024
MGI 6.23
The Jackson Laboratory